Ignite Creation Date:
2024-05-06 @ 4:14 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04922853
Status:
RECRUITING
Last Update Posted:
2022-03-31
First Post:
2021-06-04
Brief Title:
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for LowIntermediate Risk IIIII Rectal Cancer
Sponsor:
West China Hospital
Organization:
West China Hospital
Study Overview
Official Title:
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for LowIntermediate Risk IIIII Rectal Cancera Prospective Non-inferior Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COPEC
Brief Summary:
To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low intermediate risk stage IIIII rectal cancer
Detailed Description:
Neoadjuvant Chemotherapy alone has showed much benefit for low intermediate risk stage IIIII rectal cancer which would be verified by the PROSPECT trial However the effect of the Neoadjuvant chemotherapy was heterogeneous in different patients Its important to verify those chemo-resistant cases as early as possible So that this trial will compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low intermediate risk stage IIIII rectal cancer to explore whether those chemotherapeutic non-responders after 2 cycles Capox was non-inferior to those after 4 cycles chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None